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Introduction
Focal adhesions are integrin-mediated cell matrix junctions 
connecting the ECM to the actin cytoskeleton. The ECM pro  teins 
bind to the extracellular domains of integrin het    erodimers, 
whereas the actin stress fi  bers link to integrin cytoplasmic tails 
via large molecular complexes. These complexes comprise 
  actin-binding/modulating proteins, protein kinases, phospha-
tases, GTPases, and adaptor proteins (Lo, 2006) and are targets 
of regulatory signals that control focal adhesions’ function, 
including cell adhesion, migration, proliferation, differentiation, 
and gene expression (Schwartz et al., 1995; Hynes, 2002). 
Dysregulation of these components is associated with diseases 
such as cancer (Lo, 2006).
Tensin is a gene family with four members (tensin1, 
tensin2, tensin3, and cten), and their encoding proteins are 
localized to the cytoplasmic side of focal adhesions. Tensin1, 
the prototype of the family, interacts with actin fi  laments in 
multiple ways (Lo et al., 1994) and contains an Src homology 
2 (SH2) domain that binds to phosphotyrosine-containing 
proteins (Davis et al., 1991; Cui et al., 2004), followed by a 
phosphotyrosine binding (PTB) domain that interacts with the 
NPXY motif on the β integrin cytoplasmic tails (Calderwood 
et al., 2003). Tensin2 and -3 have domain structures that are 
very similar to those of tensin1, although the central regions are 
diverse (Lo, 2004). On the other hand, cten (C-terminal tensin 
like) is a distant member of the family with smaller molecular 
mass, and the only sequence homologous region is the SH2 and 
PTB domains. The cten gene localizes to chromosome 17q21, a 
region frequently deleted in prostate cancer (Gao et al., 1995; 
Hagmann et al., 1996; Williams et al., 1996), and its expression 
is reduced or absent in prostate cancer (Lo and Lo, 2002), 
suggesting a role of cten as a tumor suppressor. However, the 
potential mechanism has not been well understood. In this 
study, we have identifi  ed deleted in liver cancer 1 (DLC-1) as 
one of the binding partners of cten, mapped the binding sites on 
cten and DLC-1, and demonstrated the biological relevance of 
this interaction. Our results provide new insight into how cten 
may be involved in preventing tumor formation.
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T
he tensin family member cten (C-terminal tensin 
like) is an Src homology 2 (SH2) and phosphotyro-
sine binding domain–containing focal adhesion 
molecule that may function as a tumor suppressor. How-
ever, the mechanism has not been well established. We 
report that cten binds to another tumor suppressor,  deleted 
in liver cancer 1 (DLC-1), and the SH2 domain of cten is 
responsible for the interaction. Unexpectedly, the interac-
tion between DLC-1 and the cten SH2 domain is indepen-
dent of tyrosine phosphorylation of DLC-1. By site-directed 
mutagenesis, we have identiﬁ   ed several amino acid 
residues on cten and DLC-1 that are essential for this 
interaction. Mutations on DLC-1 perturb the interaction 
with cten and disrupt the focal adhesion localization 
of DLC-1. Furthermore, these DLC-1 mutants have lost 
their tumor suppression activities. When these DLC-1 mu-
tants were fused to a focal adhesion targeting sequence, 
their tumor suppression activities were signiﬁ   cantly 
  restored. These results provide a novel mechanism 
whereby the SH2 domain of cten-mediated focal adhe-
sion localiza  tion of DLC-1 plays an essential role in its 
  tumor suppression activity.
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Results and discussion
To understand cten’s biological function and the potential 
mechanism involved, we set up experiments to identify cten-
associated proteins by yeast two-hybrid assay, mass spectrometry 
analysis, and candidate screenings. One of the molecules 
identifi  ed is DLC-1, which is a tumor suppressor that regulates 
actin stress fi  bers and cell adhesion and inhibits tumor cell 
growth and migration (Yuan et al., 1998, 2003b; Ng et al., 2000; 
Goodison et al., 2005; Wong et al., 2005). Its rat homologue, 
p122RhoGAP (RhoGTPase-activating protein), is isolated as 
a phospholipase Cδ1–interacting protein (Homma and Emori, 
1995) and is localized to caveolae (Yamaga et al., 2004) and 
focal adhesions (Kawai et al., 2004). To demonstrate the relation 
between DLC-1 and cten, an expression vector encoding GFP 
or GFP–DLC-1 was transfected into cten-expressing A549 
cells and molecules associated with GFP–DLC-1 or GFP were 
immunoprecipitated with anti-GFP antibodies. The immunoblot 
analysis indicated that endogenous cten was present in the 
GFP–DLC-1–associated complexes, but not in the GFP control 
(Fig. 1 A). The reciprocal experiment also detected GFP–DLC-1 in 
the cten immunocomplexes (unpublished data). The interaction 
was further examined by a luciferase reporter–based mammalian 
two-hybrid assay. The positive interaction shown by a fourfold 
enhancement of luciferase activity was detected when DLC-1 
and cten were cotransfected into NIH 3T3 cells (Fig. 1 B). 
  Finally, to test the interaction between endogenous DLC-1 
and cten, we screened numerous cell lines and found that 
MLC-SV40 (immortalized normal prostate epithelialcell line) 
expressed both cten and a low level of DLC-1. This cell line 
was used for coimmunoprecipitation assay, and the results 
demonstrated that cten interacted with endogenous DLC-1 
(Fig. 1 C).
To demonstrate the direct interaction and map the regions 
responsible for the binding, we have applied yeast two-hybrid 
assay. As expected, the full-length DLC-1 binds to intact cten 
(Fig. 2, A and B). With truncated constructs, the interaction 
regions were initially mapped to the N-terminal half (1–800) 
of DLC-1 and the C-terminal region (327–715) of cten, 
which contains the SH2 and PTB domains. We generated and 
examined constructs containing only the SH2 or PTB domain. 
Surprisingly, it was the SH2 domain that interacted with DLC-1. 
Because all tensin members contain the highly conserved SH2 
domains (Lo, 2004), we predicted that they were likely to bind 
to DLC-1 as well. Indeed, DLC-1 interacted with SH2 domains 
of tensin1, -2, and -3 in the yeast two-hybrid assay (Fig. 2 B). 
Furthermore, when the arginine residue at the critical position, 
βB5, in the SH2 domain of cten was mutated into alanine 
(R474A), it abolished the interaction. Therefore, we have 
confi  rmed that the SH2 domain of cten binds to DLC-1. By a 
similar approach, we have defi  ned the binding region on DLC-1 
(1–535; Fig. 2 B).
Figure 1. Identiﬁ  cation of DLC-1 as a cten binding partner. (A) A549 cells 
were transfected with pEGFP (lane 1) or pEGFP–DLC-1 (lane 2). Cell lysates 
were coimmunoprecipitated with anti-GFP and analyzed by immunoblotting 
(IB) with anti-cten (left) or anti-GFP (right). The arrow indicates cten, and 
arrowheads show GFP and GFP–DLC-1. (B) NIH 3T3 cells in 24-well dishes 
were cotransfected with pCMV-AD-cten, and pCMV-BD vector with no 
insert as a negative control (column 1), pCMV-BD-DLC-1 (column 2), pCMV-
BD-DLC-1
S440A (column 3), or pCMV-BD-DLC-1
Y442F (column 4), and together 
with the reporter plasmid pFR-Luc. The luciferase activities were measured 
by luminometry and shown as relative light units (RLU) per milligram of 
cellular proteins. Data are from two independent triplicate experiments. 
Error bars indicate mean ± SD. (C) MLC SV-40 cell lysates were 
coimmunoprecipitated with normal rabbit serum (lane 1) or anti–DLC-1 
(lane 2) and analyzed by immunoblotting with anti-cten (left) or anti–DLC-1 
(right). The arrow indicates cten, and the arrowhead shows DLC-1.
Figure 2.  Determination of binding regions on cten and DLC-1 and their 
binding speciﬁ  cities. (A) Schematic diagram of cten and DLC-1 and their 
segments that were used for mapping the binding sites. (B) AH109 yeast 
cells transformed with the indicated plasmids and grown on two-dropout 
plates were restreaked on four-dropout plates. (C) Bacterial lysates 
containing Xpress–DLC-1 (113–535) were incubated with immobilized 
GST (lane 1) or GST-cten SH2 (lane 2). After washing, the associated 
proteins were analyzed by immunoblotting (IB) with anti-Xpress antibody. 
(D) 0.5 μg of puriﬁ  ed GST-cten SH2 (lane 1), GST-Src SH2 (lane 2), and 
GST-p85 SH2 (lane 3) recombinant proteins were incubated with DLC-1 
peptide (CSRLSIY
442DNVPG) immobilized on agarose beads. After 
washing, the associated proteins were analyzed by immunoblotting with 
anti-GST antibody. (E) 0.5 μg of puriﬁ   ed GST-cten SH2 recombinant 
proteins were incubated with DLC-1 peptide (CSRLSIY
442DNVPG; lane 1), 
tyrosine-phosphorylated DLC-1 peptide (CSRLSIpY
442DNVPG; lane 2), 
EGFR peptide (CSVQNPVY
1086HNQP; lane 3), or tyrosine-phosphor-
ylated EGFR peptide (CSVQNPVpY
1086HNQP; lane 4) immobilized on 
agarose beads. After washing, the associated proteins were analyzed 
by immunoblotting with anti-GST antibody.CTEN AND DLC-1 INTERACTION • LIAO ET AL. 45
The SH2 domain is known as a binding motif for phos-
photyrosine-containing peptides. However, yeast cells contain a 
very low level of, if any, phosphotyrosine. To test that this SH2–
DLC-1 interaction is truly independent of tyrosine phosphory-
lation and to further map the binding region, because shorter 
fragments of N-terminal DLC-1 displayed self-activation 
activity in the yeast two-hybrid system, we performed a pull-
down assay using recombinant GST-SH2 and Xpress–DLC-1 
fragments expressed in bacteria, which contain no tyrosine 
kinase at all. The result showed that recombinant SH2 remained 
bound to DLC-1 (113–535; Fig. 2 C). Together with our results 
using synthetic peptides for binding (see the following 
paragraph), we have confi  rmed that the interaction is phospho-
tyrosine independent.
It has been shown that the interaction of the SH2 domain 
of SAP (also named SH2D1A), the gene product mutated 
in X-linked lymphoproliferative syndrome, to lymphocyte 
coreceptor SLAM is independent of tyrosine phosphorylation 
(Sayos et al., 1998). In fact, the SH2 domain of SAP interacts with 
non–tyrosine-phosphorylated peptides containing S/TIYxxI/V 
(Poy et al., 1999), and we found that there was one such site, 
440SIYDNV, in DLC-1. Coincidentally, this site resides in the 
SH2 binding region (113–535). When either S440 or Y442 was 
mutated (S440A or Y442F), the interaction was abolished in 
both mammalian and yeast two-hybrid assays (Fig. 1 B and 
Fig. 2 B), demonstrating that this is indeed the essential site on 
DLC-1 for binding to the SH2 domain of cten. Interestingly, 
although the SAP SH2 domain binds to a similar motif, SAP 
SH2 domain does not interact with DLC-1 (Fig. 2 B). We further 
tested whether DLC-1 might be able to interact with other SH2 
domain containing proteins, such as Src and p85, by a pull-
down assay using the DLC-1 peptide (CSRLSIY
442DNVPG)–
conjugated beads. As shown in Fig. 2 D, only cten SH2 domain 
could interact with the DLC-1 peptide. In addition, cten SH2 do-
main did not bind to an EGFR peptide (CSVQNPVY
1086HNQP) 
regardless of whether Y1086 was phosphorylated (Fig. 2 E). 
These results demonstrated the binding specifi  city between the 
DLC-1 and cten SH2 domain. Furthermore, we tested whether syn-
thetic tyrosine-phosphorylated peptide (CSRLSIpY
442DNVPG) 
interacted with the cten SH2 domain and found that phosphory-
lation on Y442 slightly reduced the interaction (Fig. 2 E). Be-
cause no report had documented the tyrosine phosphorylation 
of DLC-1 and we did not detect tyrosine phosphorylation 
of DLC-1 (113–535) when incubated with recombinant Src 
(unpublished data), the biological relevance of this reduced 
binding is currently unknown.
Because both cten and DLC-1 localize to focal adhesions 
and a previous study found that p122RhoGAP (117–533; Kawai 
et al., 2004), corresponding to DLC-1 (125–541), contained 
the focal adhesion targeting site, which overlapped with the 
SH2 binding site identifi  ed in this study, we speculated that 
the DLC-1 and cten interaction might be responsible for recruit-
ing DLC-1 to focal adhesions. If this is the case, S440A and Y442F 
DLC-1 mutants would not be able to localize to focal adhesions. 
In contrast to the colocalization of cten and GFP–DLC-1 
(1–535) at focal adhesion sites, the GFP–DLC-1 (1–535)
S440A 
or GFP–DLC-1 (1–535)
Y442F was diffusely distributed in the 
cytoplasm (Fig. 3 A), indicating that the SH2 binding site 
is essential for DLC-1’s focal adhesion localization. The 
protein expressions of these constructs were confi  rmed  by 
Figure 3.  Subcellular localization of DLC-1 and its recruitment by cten 
SH2. (A) A549 cells grown on coverslips were transfected with pEGFP–
DLC-1 (1–535), pEGFP–DLC-1 (1–535)
S440A, or pEGFP–DLC-1 (1–
535)
Y442F. After labeling with anti-cten antibodies followed by Alexa Fluor 
594–conjugated secondary antibody, cells were visualized with a 
confocal microscope. Arrows indicate cten and GFP fusion protein 
colocalized at focal adhesions. Arrowheads show only cten at focal 
adhesions. About 100 GFP-positive cells were examined in each 
transfection. More than 90% of GFP-positive cells showed focal adhesion 
localization when transfected with GFP–DLC-1 (1–535), and no GFP-
positive cells transfected with DLC-1 mutants showed focal adhesion 
localization. Cell lysates from A549 transiently expressing GFP–DLC-1 
(1–535; lane 1), GFP–DLC-1(1–535)
S440A (lane 2), or GFP–DLC-1 
(1–535)
Y442F (lane 3) were immunoprecipitated with anti-GFP and ana-
lyzed by immunoblotting with anti-GFP to show similar amounts, and 
correct sizes of recombinant proteins were expressed. (B) A549 cells 
grown on coverslips were cotransfected with pDsRed1/pEGFP–DLC-1 
(1–535) or pDsRed1-cten SH2-SKL/pEGFP-DLC-1 (1–535). Cells were vis-
ualized with a confocal microscope. Note that the DsRed-cten SH2-SKL 
and GFP–DLC-1 (1–535) were colocalized at peroxisomes (arrows), 
although some GFP–DLC-1 (1–535) proteins were still detected at focal 
adhesions (at different focus plane; not depicted), as predicted, because 
of the presence of endogenous tensins in A549 cells. Arrowheads show 
only GFP–DLC-1 (1–535) at focal adhesions. Bars, 10 μm.JCB • VOLUME 176 • NUMBER 1 • 2007  46
immunoblotting (Fig. 3 A). To further demonstrate that the cten 
SH2 domain is crucial for recruiting DLC-1 to a subcellular 
compartment, we generated a DsRed-cten SH2-SKL construct 
so that the DsRed-cten SH2 domain would be fused with the 
peroxisomal targeting peptide, SKL (Gould et al., 1989), at the 
C terminus when expressed and be targeted to peroxisomes. 
As shown in Fig. 3 B, although the DsRed was distributed in the 
cytoplasm, the DsRed-cten SH2-SKL proteins were accumu-
lated at peroxisomes. When these constructs were cotransfected 
with GFP–DLC-1 (1–535), the DsRed-cten SH2-SKL was able 
to recruit some GFP–DLC-1 (1–535) to peroxisomes, demon-
strating that cten SH2 alone is suffi  cient for the interaction and 
recruitment of DLC-1.
DLC-1 was identifi  ed as a candidate tumor suppressor, 
and its expression was lost or down-regulated in various can-
cers, including liver, breast, lung, brain, stomach, colon, and 
prostate, because of either genomic deletion or aberrant DNA 
methylation (Yuan et al., 1998, 2003a; Ng et al., 2000; Kim et al., 
2003; Plaumann et al., 2003; Wong et al., 2003; Song et al., 
2006). It has been reported that reexpression of DLC-1 in liver, 
breast, and lung cancer cell lines inhibits cancer cell growth 
(Yuan et al., 2003b, 2004; Zhou et al., 2004; Goodison et al., 
2005; Wong et al., 2005), supporting its role as a tumor suppres-
sor. DLC-1 contains three conserved domains: the sterile α mo-
tif (SAM), RhoGAP, and steroidogenic acute regulatory-related 
lipid transfer (START) domains (Fig. 2 A). SAM domains have 
been implicated in protein–protein interactions and are highly 
versatile in their binding partners. Some SAM domains may 
bind to each other to form homodimers or polymers, whereas 
others can interact with other proteins, or even RNA and DNA 
(Qiao and Bowie, 2005). START domains are predicted to con-
tain a binding pocket for lipids, and modifi  cations in the pocket 
may determine ligand binding specifi  city and function (Iyer et al., 
2001). RhoGAP domains convert the active GTP-bound Rho 
proteins to the inactive GDP-bound state and function as nega-
tive regulators of RhoGTPases, which are involved in actin 
cytoskeleton organization, focal adhesion assembly, and cell 
proliferation (Moon and Zheng, 2003), and dysregulation of 
Rho activity has been implicated in tumorigenesis (Jaffe and 
Hall, 2002). A recent study demonstrated that the RhoGAP and 
START domains of DLC-1 are required for its tumor suppres-
sion activity (Wong et al., 2005). However, these two domains 
are not suffi   cient because expression of the RhoGAP and 
START domains alone does not inhibit tumor cell growth (Wong 
et al., 2005). In fact, the shortest fragment with the suppression 
activity contains, in addition to the RhoGAP and START 
  domains, a region overlapping with the SH2 binding site, which 
is critical for focal adhesion localization. We hypothesized that 
the appropriate focal adhesion localization is essential for 
DLC-1’s functions, including tumor cell suppression activity. 
Figure 4.  Colony formation and cell growth assays in MDA-MB-468 cells 
transfected with wild-type and mutant DLC-1. (A) Cells were transfected 
with the indicated constructs. After being cultured in media containing 0.8 
mg/ml G418 for 2 wk, G418-resistant colonies were stained with crystal 
violet. (B) The histogram shows the colony formation assay of GFP (column 1), 
GFP–DLC-1 (column 2), GFP–DLC-1
S440A (column 3), GFP–DLC-1
Y442F 
(column 4), GFP–FAB–DLC-1 (column 5), GFP–FAB–DLC-1
S440A (column 6), 
and GFP–FAB–DLC-1
Y442F (column 7) from four independent experiments. 
(C) G418-resistant MDA-MB-468 cells (2 × 10
5) expressing the indicated 
proteins were seeded in triplicate in 60-mm dishes. Cells were harvested at 
24-h intervals for 4 d, and the numbers of viable cells were counted by 
trypan blue exclusion assay with a hematocytometer. Error bars indicate 
mean ± SD. (D) Cell lysates from MDA-MB-468 transfected with GFP vec-
tor (lane 1), GFP–DLC-1 (lane 2), GFP–DLC-1
S440A (lane 3), GFP–DLC-1
Y442F 
(lane 4), GFP–FAB–DLC-1 (lane 5), GFP–FAB–DLC-1
S440A (lane 6), or GFP–
FAB–DLC-1
Y442F (lane 7) were immunoprecipitated with anti-GFP and 
analyzed by immunoblotting with anti-GFP to show similar expression 
levels and correct sizes of recombinant proteins. The arrow indicates GFP, 
and arrowheads show GFP–DLC-1 and GFP–FAB–DLC-1 fusion proteins. 
(E) A549 cells grown on coverslips were transfected with pEGFP–FAB–DLC-1, 
pEGFP–FAB–DLC-1
S440A, or pEGFP–FAB–DLC-1
Y442F. After labeling with 
anti-cten antibodies followed by Alexa Fluor 594–conjugated secondary 
antibody, cells were visualized with a confocal microscope. Arrows indicate 
cten and GFP fusion protein colocalized at focal adhesions. Bars, 10 μm.CTEN AND DLC-1 INTERACTION • LIAO ET AL. 47
To test this, we performed the colony formation assay using 
MDA-MB-468 breast cancer cell line, in which the growth was 
suppressed by DLC-1 overexpression (Yuan et al., 2003b). Con-
sistent with a previous report, wild-type DLC-1 was able to 
suppress MDA-MB-468 cell growth. However, neither GFP–
DLC-1
S440A nor GFP–DLC-1
Y442F could inhibit MDA-MB-468 
cell growth (Fig. 4, A and B). In agreement with these results, 
the growth curve of MDA-MB-468 cells was signifi  cantly 
slower with wild-type DLC-1 (Fig. 4 C). Thus, the SH2 binding 
site is not only essential for DLC-1’s focal adhesion localization 
but also critical for its tumor suppression activity. To further 
address the importance of the focal adhesion localization of 
DLC-1 to its tumor suppression activity, we fused wild-type and 
mutant DLC-1 with the N-terminal focal adhesion binding (FAB) 
site (aa 65–360) of chicken tensin1 (Chen and Lo, 2003), which 
is not conserved in cten. This FAB fusion forced the focal adhe-
sion localization of GFP–FAB–DLC-1, GFP–FAB–DLC-1
S440A, 
and GFP–FAB–DLC-1
Y442F (Fig. 4 E). From the colony forma-
tion assay, the constitutive focal adhesion localizations of these 
molecules signifi  cantly enhanced the suppression activities of 
DLC-1
S440A and DLC-1
Y442F mutants (Fig. 4, A and B). There-
fore, the focal adhesion localization of DLC-1 is essential for its 
tumor suppression activity. Nonetheless, the suppression activi-
ties of DLC-1
S440A and DLC-1
Y442F were not fully restored by 
linking to FAB. It is possible that the cten–DLC-1 interaction is 
not just for recruiting DLC-1 to focal adhesions but also for 
regulating its activity. In addition, because we fused DLC-1 
with the N-terminal FAB site of tensin1 and DLC-1 normally 
binds to the C-terminal SH2 domains of tensins, these FAB 
fusion mutant proteins were not targeted to the precise position 
within the focal adhesion complexes. This spatial discrepancy 
may also contribute to the weaker suppression activities observed 
in GFP–FAB–DLC-1
S440A and GFP–FAB–DLC-1
Y442F.
In this study, we have demonstrated that the tumor 
suppressor DLC-1 interacts with the SH2 domains of cten and 
other tensins as well. Although the SH2 binding site on DLC-1 
also contains a critical tyrosine residue (Y442), the interaction 
does not rely on the phosphorylation of Y442. However, the 
phosphorylation of Y442 does reduce the interaction. This is a 
novel binding feature of tensins’ SH2 domains. Furthermore, 
this interaction is highly specifi  c for the SH2 domain of tensin 
family, as the SH2 domains of SAP, Src, and p85 all fail to bind 
to DLC-1. The biological signifi   cance of the cten–DLC-1 
interaction is illustrated by mislocalization and the loss of tumor 
suppression activities of DLC-1
S440A and DLC-1
Y442F mutants. 
Furthermore, the suppression activities of these mutants could 
be rescued by tagging with FAB sequence. Therefore, in 
addition to genomic deletion and promoter hypermethylation, 
mislocalization of the DLC-1 protein may be another mechanism 
for acquiring tumorigenicity involving DLC-1 dysregulation. 
In this regard, further investigations on the DLC-1 protein 
localization in cancer samples with “normal” DLC-1 expression 
level are highly warranted. Based on these fi  ndings, we propose 
that DLC-1 is recruited to focal adhesion sites by one or more 
tensin members, depending on cell types and tissues. At the 
focal adhesion site, the RhoGAP domain of DLC-1 negatively 
regulates Rho small GTPase, which organizes actin stress fi  bers, 
and focal adhesion turnover, in turn, mediates cell migration 
and proliferation. When the expression and/or localization of 
DLC-1 are compromised, the cells are more susceptible for 
transformation. The fact that DLC-1 is able to bind to all tensins 
through their SH2 domains may explain why DLC-1 relies on 
tensin members for its normal localization and function, yet 
DLC-1–knockout mice (Durkin et al., 2005) displayed a 
more severe phenotype than tensin1 or -3 single-knockout mice 
(Lo et al., 1997; Chiang et al., 2005). It may require double or 
even triple tensin knockout to observe the defect results from 
mislocalization of DLC-1. On the other hand, recruiting DLC-1 
to focal adhesion sites may not be the only function for cten. It is 
known that activated caspase3 cleaves cten at the DSTD
570¯S, 
site generating two cten fragments: 1–570 and 571–715 (Lo 
et al., 2005). The later contains the PTB domain alone, which 
by itself is able to reduce cell growth by inducing apoptosis (Lo 
et al., 2005). In this case, the loss of cten expression may lead 
to uncontrolled cell growth and result in cell transformation. 
Together with our current fi  ndings, cten may function as a tumor 
suppressor in multiple ways.
Materials and methods
Plasmid constructions and mutagenesis
The full-length coding sequence of the DLC-1 gene was ampliﬁ  ed  from 
human kidney cDNA. The full-length and truncated fragments of DLC-1 
were subcloned in frame into mammalian expression vector pEGFP-C2 
(CLONTECH Laboratories, Inc.), yeast expression vector pGBKT7 (CLON-
TECH Laboratories, Inc.), and mammalian two-hybrid vector pCMV-BD 
(Stratagene). The full-length and truncated fragments of cten were 
constructed into pGADT7 (CLONTECH Laboratories, Inc.) and pCMV-AD 
(Stratagene) for yeast and mammalian two-hybrid analyses, respectively. 
The cDNA encoding the SH2 domain of SAP was ampliﬁ  ed from human 
thymus cDNA and subcloned into pGADT7. The corresponding coding 
regions of the SH2 domains of tensin1, tensin2, tensin3, and cten were 
subcloned into pGADT7 and bacterial expression vector pGEX-5X-1 (GE 
Healthcare). The region encoding DLC-1 residues 113–535 was inserted 
into pTrcHis containing His and Xpress tags (Invitrogen). The mutations in 
DLC-1 (S440A and Y442F) and cten SH2 domain (R474A) were generated 
by site-directed mutagenesis. The corresponding coding regions of the SH2 
domains of Src and p85 were subcloned into pGEX-5X-1. To construct 
pDsRed1-cten SH2-SKL, SKL residues were introduced into the C terminus 
of cten SH2 fragment by PCR. The resulting ampliﬁ  ed PCR products were 
then ligated into pDsRed1-C1 (CLONTECH Laboratories, Inc.). The 
N-terminal FAB site of chicken tensin1 (residues 65–360; Chen and Lo, 
2003) was used to construct fusions to the N terminus of DLC-1 in pEGFP–
DLC-1, pEGFP–DLC-1
S440A, or GFP–DLC-1
Y442F plasmids. All constructs 
were veriﬁ  ed by DNA sequencing.
Cell culture and transfection
MLC-SV40 cells, a gift from J. Rhim (Uniform Services University, Bethesda, 
MD), were cultured in keratinocyte serum-free medium supplemented with 
antibiotics, 5 ng/ml human recombinant EGF, and 0.05 mg/ml bovine 
pituitary extract (Invitrogen). A549, NIH3T3, and MDA-MB-468 cells 
purchased from American Type Culture Collection were cultured in DME 
supplemented with antibiotics and 10% fetal bovine serum. A549 cells 
were transfected using Lipofectamine 2000 (Invitrogen), whereas NIH 3T3 
and MDA-MB-468 cells were transfected using SuperFect transfection 
reagent (QIAGEN) according to the manufacturer’s instructions.
Immunoprecipitation and immunoblotting
Transiently transfected A549 or MDA-MB-468 cells with GFP fusion 
constructs were lysed in immunoprecipitation buffer (1% Triton X-100, 
50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 10 μg/ml aprotinin, 
10 μg/ml leupeptin, 1 μg/ml pepstatine, and 1 μM PMSF) and cleared 
by centrifugation at 14,000 g for 15 min at 4°C. The clariﬁ  ed cell lysates 
were incubated with 1 μg of an anti-GFP goat polyclonal antibody 
(Rockland) by rotating at 4°C for 1 h, followed by the addition of 30 μl JCB • VOLUME 176 • NUMBER 1 • 2007  48
of 50% of protein A–Sepharose slurry (GE Healthcare) for 1 h. The 
protein A beads were collected by centrifugation and washed with 
immunoprecipitation buffer. Samples were then boiled in protein loading 
buffer and subjected to immunoblotting analyses using anti-GFP rabbit 
polyclonal antibodies (Santa Cruz Biotechnology, Inc.).
For coimmunoprecipitation, 24 h after transfection, A549 cells 
expressing the GFP or the GFP–DLC-1 constructs were lysed in coimmuno-
precipitation buffer (0.1% Triton X-100, 25 mM Tris-HCl, pH 8.0, 50 mM 
NaCl, 0.2 mM EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 μg/ml 
pepstatine, and 1 μM PMSF). Cell lysates were then sheared by passing 
through a syringe needle, and the cell debris was removed by centrifuga-
tion at 14,000 g for 15 min at 4°C. 1.2 mg of the clariﬁ  ed cell lysates 
were incubated with 2 μg of an anti-GFP goat polyclonal antibody 
(Rockland) by rotating at 4°C for 4 h, followed by the addition of protein 
A–Sepharose. Samples were subjected to immunoblotting analyses using 
anti-cten (Lo and Lo, 2002) and anti-GFP rabbit polyclonal antibodies 
(Santa Cruz Biotechnology, Inc.).
A similar approach was performed for coimmunoprecipitation of 
endogenously expressed DLC-1 in MLC-SV40, except that 3 mg of the 
clariﬁ  ed MLC-SV40 cell lysates were incubated with 1 μg of an anti–DLC-1 
rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc.) by rotating at 
4°C overnight. Immunoblotting analyses were performed using anti-cten 
rabbit polyclonal antibodies and anti–DLC-1 mouse monoclonal antibodies 
(BD Biosciences).
Mammalian two-hybrid assay
Plasmids (1 μg of each mammalian two-hybrid construct and 0.5 μg of 
pFR-Luc reporter) were transfected into NIH 3T3 cells using SuperFect. Cells 
were harvested 24 h after transfection. Fireﬂ  y luciferase and activities in 
the cell extracts were determined by the procedure using Luciferase Assay 
System (Promega) and measured by luminometry.
Yeast two-hybrid analyses
To assay the interaction between DLC-1 and cten, the Saccharomyces 
  cerevisiae strain AH109 was transformed with combinations of cten fragments 
in the activation domain (AD) plasmid, pGADT7, together with each of the 
DLC-1 fragments in the DNA-binding domain (DNA-BD) plasmid, pGBKT7. 
In brief, 5 ml of overnight culture of AH109 in YPD medium was diluted 
50-fold and allowed to grow for another 4 h at 30°C. The yeast cells were 
harvested by centrifugation at 2,000 g for 15 min at room temperature 
and washed twice with 25 ml of sterile water. The cells were resuspended 
in 0.5 ml of 0.1 M lithium acetate (LiAc). 100 μl of competent cells were 
mixed with 600 μl TE-LiAc-PEG (1× TE, 0.1 M LiAc, and 40% polyethylene 
glycol [mol wt 3,350]), 10 μl of salmon sperm DNA, and 1 μg of each 
plasmid. After incubation at 30°C for 30 min, 70 μl of DMSO was added 
to the cells and heat shocked at 42°C for 15 min. The transformation 
mixture was centrifuged and washed with 1 ml of sterile water. The cell 
pellets were subsequently resuspended in 1× TE buffer and plated on 
nutritional selection agar lacking leucine and tryptophan. The resulting 
colonies were then restreaked on quadruple dropout plates lacking Ade, 
His, Leu, and Trp.
In vitro pull-down assay
For GST pull-down assay, the cDNAs encoding the SH2 domain of cten 
were subcloned into pGEX-5X-1 to generate GST fusion proteins (GST-cten 
SH2). The corresponding coding region of 113–535 amino acids of 
human DLC-1 was ligated into pTrcHis to express an Xpress-tagged protein, 
Xpress–DLC-1 (113–535). GST-cten SH2 proteins were expressed in and 
puriﬁ  ed from Escherichia coli using glutathione-agarose (Sigma-Aldrich). 
20 μg of GST or GST-cten SH2 on glutathione-agarose beads was mixed 
with 2 mg of bacterial lysates expressing Xpress–DLC-1 (113–535) in 
extraction buffer (0.1% Triton X-100, 50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, and 0.2 mM EDTA). After incubation on a rotator for 3 h at 4°C, the 
slurry was pelleted by centrifugation and washed ﬁ  ve times with ice-cold 
extraction buffer. The pellet was resuspended in protein loading buffer and 
subjected to immunoblotting analyses using an anti-Xpress mouse 
monoclonal antibody (Invitrogen).
For peptide pull-down assay, peptides were covalently bound to 
Sulfolink resin (Pierce Chemical Co.) via terminal cysteine residues 
following the manufacturer’s instructions and used in pull-down assays with 
eluted GST fusion proteins. GST fusion proteins were puriﬁ  ed  using 
glutathione-agarose in PBS containing 0.2% Triton X-100 and eluted by 
elution buffer (10 mM reduced glutathione in 10 mM Tris-HCl, pH 9.5). 
Eluted GST fusion proteins were then concentrated in PBS buffer using 
Centricon (Millipore). 30 μl of 50% slurry of peptide beads ( 10 μg 
peptides immobilized) were incubated with 0.5 μg GST fusion protein in 
1 ml PBS buffer containing 0.1% Triton X-100 by rotating at 4°C for 1 h. 
After extensive washes, samples were boiled in protein loading buffer and 
subjected to immunoblotting analyses using anti-GST mouse monoclonal 
antibodies (Cell Signaling).
Immunoﬂ  uorescence microscopy
A549 cells grown on glass coverslips were transfected and incubated at 
37°C in 5% CO2 for 10–16 h before microscopic imaging. Cells were 
ﬁ  xed with methanol at −20°C. After rinsing with PBS, cells were incubated 
with 1:25 anti-cten rabbit polyclonal antibody for 2 h. Samples were then 
incubated with 1:800 Alexa Fluor 594–conjugated secondary antibody 
(Invitrogen) for 1 h and visualized with a confocal microscope (LSM 510; 
Carl Zeiss MicroImaging, Inc.).
Colony formation assay
MDA-MB-468 cells were seeded in a 6-well plate at 2 × 10
5 cells per well. 
16 h later, 2 μg of pEGFPC2 vector or various DLC-1 constructs (pEGFP–
DLC-1, pEGFP–DLC-1
S440A, pEGFP–DLC-1
Y442F, pEGFP–FAB–DLC-1, pEGFP–
FAB–DLC-1
S440A, or pEGFP–FAB–DLC-1
Y442F) were transfected into the cells. 
After 48 h, the cells were seeded in a 6-well plate at a density of 10
4 cells 
per well and selected by 0.8 mg/ml G418 (Geneticin; Invitrogen) for 2 wk. 
Colony formation efﬁ  ciency was determined by counting the G418-resistant 
colonies stained with crystal violet solution (0.25% crystal violet and 3.7% 
formaldehyde in 80% methanol).
Cell growth analysis
MDA-MB-468 cells were seeded in a 6-well plate at 2 × 10
5 cells per well. 
16 h later, 2 μg of pEGFPC2 vector or various DLC-1 constructs (pEGFP–
DLC-1, pEGFP–DLC-1
S440A, or pEGFP–DLC-1
Y442F) were transfected into the 
cells. After 48 h, the cells were seeded in 100-mm dishes and selected by 
0.8 mg/ml G418 for 6 d. Cells were then collected and seeded in triplicate 
in 60-mm dishes at 2 × 10
5 cell density. Cells were harvested at 24-h 
intervals for 4 d, and the numbers of viable cells were counted by trypan 
blue exclusion assay with a hematocytometer.
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